Cara Therapeutics to Present at the 20th Annual Needham Healthcare Conference
April 07 2021 - 4:01PM
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company
focused on developing and commercializing new chemical entities
designed to alleviate pruritus by selectively targeting peripheral
kappa opioid receptors, or KORs, today announced that Derek
Chalmers, Ph.D., D.Sc., President and Chief Executive Officer, will
participate in a fireside chat at the 20th Annual Needham
Healthcare Conference on Wednesday, April 14, 2021 at 2:15 p.m. ET.
A live webcast of the presentation can be
accessed under "Events & Presentations" in the News &
Investors section of the Company's website
at www.CaraTherapeutics.com. An archived webcast recording
will be available on the Cara website for approximately 30
days.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biopharmaceutical company
focused on developing and commercializing new chemical entities
designed to alleviate pruritus by selectively targeting peripheral
kappa opioid receptors, or KORs. Cara is developing a novel and
proprietary class of product candidates, led by KORSUVA™
(CR845/difelikefalin), a first-in-class KOR agonist that targets
the body’s peripheral nervous system, as well as certain immune
cells. In two Phase 3 trials, KORSUVA Injection has demonstrated
statistically significant reductions in itch intensity and
concomitant improvement in quality of life measures in hemodialysis
patients with moderate-to-severe chronic kidney disease-associated
pruritus (CKD-aP). The U.S. Food and Drug Administration (FDA) has
accepted and granted Priority Review for the New Drug Application
(NDA) for KORSUVA™ (difelikefalin) solution for injection for the
treatment of moderate-to-severe pruritus in hemodialysis patients.
The PDUFA target action date for KORSUVA is August 23, 2021. Oral
KORSUVA™ has successfully completed a Phase 2 trial for the
treatment of pruritus in patients with CKD and is currently in
Phase 2 trials in atopic dermatitis, primary biliary cholangitis
and notalgia paresthetica patients with moderate-to-severe
pruritus.
The FDA has conditionally accepted KORSUVA™ as the trade name
for difelikefalin solution for injection. Difelikefalin is an
investigational drug product and its safety and efficacy have not
been fully evaluated by any regulatory authority.
MEDIA CONTACT: Claire LaCagnina6
Degrees315-765-1462 clacagnina@6degreespr.com
INVESTOR CONTACT:Janhavi MohiteStern Investor
Relations, Inc.janhavi.mohite@SternIR.com
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Apr 2023 to Apr 2024